Among MDR infections, particularly challenging are the infections due to difficult-to-treat MDR Gram-negatives such as P. aeruginosa because of the limited antimicrobial options available, along with reported high mortality rates.

Through the GNEG-project, which was started up in 2014, BKG Pharma is developing new candidates targeted specifically against MDR Gram-negative infections.

So far the results of our GNEG-project have exceeded all expectations. Based on innovative research and QSAR modeling we have succeeded in developing candidates with significantly enhanced effect against multiple MDR Gram-negative bacteria, including MDR strains of P. aeruginosaPasteurella sp., Klebsiella sp., Enterobacter sp. and E. coli.

Our new GNEG frontrunner compounds are currently undergoing in vitro and in vivo preclinical testing.